We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Xgeva Prevents Spread of Prostate Cancer to Bone Study Says
Xgeva Prevents Spread of Prostate Cancer to Bone Study Says
May 25, 2011
A Phase III trial has demonstrated Amgen’s bone drug Xgeva “significantly increased” bone metastasis-free survival and time to first bone metastases in men with advanced prostate cancer.